Drug Class: Proton Pump Inhibitors
- Pantoprazole is an FDA approved (2000) irreversible proton pump inhibitor (PPI) that reduces gastric acid secretion.
- Oral pantoprazole 20 or 40 mg/day was effective at healing and preventing non-steroidal anti-inflammatory drug (NSAID)-related ulcers.
- Intravenous pantoprazole was at least as effective as intravenous ranitidine in preventing ulcer rebleeding after endoscopic hemostasis.
- Oral and intravenous pantoprazole appear to be well tolerated in patients with acid-related disorders in short- and long-term trials.
- An effective agent in the management of acid-related disorders;
- – As a component of triple therapy for H. pylori eradication and
- – As monotherapy for the healing of oesophagitis and maintenance of gastro-oesophageal reflux disease.
- Has shown similar efficacy to other PPIs and greater efficacy than histamine H(2)-antagonists.